Cas No.Product NameDescription
133407-82-6MG-132MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM.
7497-07-6NSC 405020Membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor (IC50 > 100 μmol/L). D
179324-69-7BortezomibBortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
229975-97-7Atazanavir sulfateAtazanavir Sulfate is a sulfate salt form of atazanavir (BMS-232632) that is an highly potent HIV protease inhibitor with an EC50 and EC90 of 2.6~5.3 nM and 9~15 nM in cell culture.
1072833-77-2MLN2238MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.
1201902-80-8MLN 9708 analog;MLN-9708 analogMLN9708 immediately hydrolyzed to MLN2238, which is an N-capped dipeptidyl leucine boronic acid and preferentially bound to and inhibited the 20S proteasome with an IC50 value of 3.4 nM (Ki = 0.93 nM).
155213-67-5RitonavirRitonavir is an antiretroviral drug which inhibits a particular liver enzyme that normally metabolizes protease inhibitors, cytochrome P450-3A4 (CYP3A4).
1092540-56-1 Deuterated Atazanivir-D3-1Atazanivir-D3-2 is a azapeptide derivative and inhibits HIV protease.
161814-49-9AmprenavirAmprenavir is an HIV protease inhibitor with IC50 of 14.6 ng/mL in wild-type HIV isolates.
847499-27-8CEP-18770CEP-18770 is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome. Phase 1/2.
146535-11-7Tyrphostin AG 1296Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
668467-91-2LDN-57444Inhibitor of ubiquitin C-terminal hydrolase-L1 (UCH-L1) activity (Ki = 0.4 μM).
686770-61-6IWP 2IWP-2 is an inactivator of Porcn function (IC50=27 nM); inhibitor of Wnt production.
1434048-34-6GDC-0853GDC-0853 is a potent and orally BTK inhibitor.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway